{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:36:53Z","timestamp":1787020613706,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease, and its morbidity and mortality are increasing. At present, there is no specific therapy available. An exacerbated IFN-I response and cytokine storm are related to the mortality of patients with SFTS. Ruxolitinib is a Janus kinase (JAK) 1\/2 inhibitor that can block proinflammatory cytokines and inhibit the type I IFN pathway. We aimed to explore the use of ruxolitinib plus standard of care for severe SFTS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a prospective, single-arm study of severe SFTS. We recruited participants aged 18\u00a0years or older who were admitted to the hospital with laboratory-confirmed severe SFTS and whose clinical score exceeded 8 points within 6\u00a0days of symptom onset. Participants received oral ruxolitinib (10\u00a0mg twice a day) for up to 10\u00a0days. The primary endpoint was 28-day overall survival. The secondary endpoints included the proportion of participants who needed intensive care unit (ICU) admission, total cost, changes in neurologic symptoms and clinical laboratory parameters, and adverse events (AEs) within 28\u00a0days. A historical control group (HC group,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926) who met the upper criteria for inclusion and hospitalized from April 1, 2021, to September 16, 2022, was selected and 1:1 matched for baseline characteristics by propensity score matching.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between Sep 16, 2022, and Sep 16, 2023, 26 participants were recruited into the ruxolitinib treatment group (RUX group). The 28-day overall mortality was 7.7% in the RUX group and 46.2% in the HC group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0017). There was a significantly lower proportion of ICU admissions (15.4% vs 65.4%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and total hospitalization cost in the RUX group. Substantial improvements in neurologic symptoms, platelet counts, hyperferritinemia, and an absolute decrease in the serum SFTS viral load were observed in all surviving participants. Treatment-related adverse events were developed in 6 patients (23.2%) and worsened in 8 patients (30.8%), and no treatment-related serious adverse events were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings indicate that ruxolitinib has the potential to increase the likelihood of survival as well as reduce the proportion of ICU hospitalization and being tolerated in severe SFTS. Further trials are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trail registration<\/jats:title>\n                    <jats:p>ChiCTR2200063759, September 16, 2022.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-024-03421-z","type":"journal-article","created":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T20:02:39Z","timestamp":1716148959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Ruxolitinib plus standard of care in severe hospitalized adults with severe fever with thrombocytopenia syndrome (SFTS): an exploratory, single-arm trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Sai","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlu","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-3859","authenticated-orcid":false,"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"issue":"16","key":"3421_CR1","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1056\/NEJMoa1010095","volume":"364","author":"XJ Yu","year":"2011","unstructured":"Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, Zhang L, Zhang QF, Popov VL, Li C, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011;364(16):1523\u201332.","journal-title":"N Engl J Med"},{"issue":"4","key":"3421_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3201\/eid2604.191011","volume":"26","author":"Y Kobayashi","year":"2020","unstructured":"Kobayashi Y, Kato H, Yamagishi T, Shimada T, Matsui T, Yoshikawa T, Kurosu T, Shimojima M, Morikawa S, Hasegawa H, et al. Severe fever with thrombocytopenia syndrome, Japan, 2013\u20132017. Emerg Infect Dis. 2020;26(4):692\u20139.","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"3421_CR3","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3201\/eid2505.181463","volume":"25","author":"XC Tran","year":"2019","unstructured":"Tran XC, Yun Y, Van An L, Kim SH, Thao NTP, Man PKC, Yoo JR, Heo ST, Cho NH, Lee KH. Endemic Severe fever with thrombocytopenia syndrome. Vietnam Emerg Infect Dis. 2019;25(5):1029\u201331.","journal-title":"Vietnam Emerg Infect Dis"},{"issue":"12","key":"3421_CR4","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.3201\/eid2812.221183","volume":"28","author":"P Rattanakomol","year":"2022","unstructured":"Rattanakomol P, Khongwichit S, Linsuwanon P, Lee KH, Vongpunsawad S, Poovorawan Y. Severe fever with thrombocytopenia syndrome virus infection, Thailand, 2019\u20132020. Emerg Infect Dis. 2022;28(12):2572\u20134.","journal-title":"Emerg Infect Dis"},{"key":"3421_CR5","unstructured":"International Committee on Taxonomy of Viruses. Taxon details: severe fever with thrombocytopenia syndrome virus. [https:\/\/ictv.global\/taxonomy\/taxondetails?taxnode_id=202100166]."},{"issue":"1","key":"3421_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41541-020-00257-5","volume":"5","author":"NE Bopp","year":"2020","unstructured":"Bopp NE, Kaiser JA, Strother AE, Barrett ADT, Beasley DWC, Benassi V, Milligan GN, Preziosi MP, Reece LM. Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development. NPJ Vaccines. 2020;5(1):111.","journal-title":"NPJ Vaccines"},{"issue":"8","key":"3421_CR7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1473-3099(14)70718-2","volume":"14","author":"Q Liu","year":"2014","unstructured":"Liu Q, He B, Huang SY, Wei F, Zhu XQ. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis. 2014;14(8):763\u201372.","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"3421_CR8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1089\/vbz.2022.0035","volume":"22","author":"M Kim","year":"2022","unstructured":"Kim M, Hong KW, Kim SC, Kim RB, Cho MC. Analysis of clinical characteristics and laboratory data related to the prognosis of korean severe fever with thrombocytopenia syndrome patients: a single-center study. Vector Borne Zoonotic Dis. 2022;22(11):559\u201367.","journal-title":"Vector Borne Zoonotic Dis"},{"issue":"10","key":"3421_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S1473-3099(18)30293-7","volume":"18","author":"H Li","year":"2018","unstructured":"Li H, Lu QB, Xing B, Zhang SF, Liu K, Du J, Li XK, Cui N, Yang ZD, Wang LY, et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011\u201317: a prospective observational study. Lancet Infect Dis. 2018;18(10):1127\u201337.","journal-title":"Lancet Infect Dis"},{"key":"3421_CR10","first-page":"193","volume":"4","author":"Ministry of Health PRC","year":"2011","unstructured":"Ministry of Health PRC. Guideline for prevention and treatment of severe fever with thrombocytopenia syndrome (2010 version). Zhonghua Lin Chuang Gan Ran Bing Za Zhi. 2011;4:193\u20134.","journal-title":"Zhonghua Lin Chuang Gan Ran Bing Za Zhi"},{"key":"3421_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ijid.2023.03.015","volume":"130","author":"G Wang","year":"2023","unstructured":"Wang G, Xu YL, Zhu Y, Yue M, Zhao J, Ge HH, Ye XL, Liu YN, Gong XY, Zhang LG, et al. Clinical efficacy of low-dose glucocorticoid therapy for critically ill patients with severe fever with thrombocytopenia syndrome: a retrospective cohort study. Int J Infect Dis. 2023;130:153\u201360.","journal-title":"Int J Infect Dis"},{"key":"3421_CR12","doi-asserted-by":"publisher","first-page":"104807","DOI":"10.1016\/j.ebiom.2023.104807","volume":"96","author":"SS Zhang","year":"2023","unstructured":"Zhang SS, Du J, Cui N, Yang X, Zhang L, Zhang WX, Yue M, Wu YX, Yang T, Zhang XA, et al. Clinical efficacy of immunoglobulin on the treatment of severe fever with thrombocytopenia syndrome: a retrospective cohort study. EBioMedicine. 2023;96:104807.","journal-title":"EBioMedicine"},{"issue":"7","key":"3421_CR13","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/infdis\/jis452","volume":"206","author":"Y Sun","year":"2012","unstructured":"Sun Y, Jin C, Zhan F, Wang X, Liang M, Zhang Q, Ding S, Guan X, Huo X, Li C, et al. Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome. J Infect Dis. 2012;206(7):1085\u201394.","journal-title":"J Infect Dis"},{"issue":"8","key":"3421_CR14","doi-asserted-by":"publisher","first-page":"110039","DOI":"10.1016\/j.celrep.2021.110039","volume":"37","author":"H Li","year":"2021","unstructured":"Li H, Li X, Lv S, Peng X, Cui N, Yang T, Yang Z, Yuan C, Yuan Y, Yao J, et al. Single-cell landscape of peripheral immune responses to fatal SFTS. Cell Rep. 2021;37(8):110039.","journal-title":"Cell Rep"},{"issue":"49","key":"3421_CR15","doi-asserted-by":"publisher","first-page":"eabd1554","DOI":"10.1126\/sciimmunol.abd1554","volume":"5","author":"JS Lee","year":"2020","unstructured":"Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, Choi B, Nam SK, Sa M, Kwon JS, et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19. Sci Immunol. 2020;5(49):eabd1554.","journal-title":"Sci Immunol"},{"issue":"3","key":"3421_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/bjh.16174","volume":"187","author":"E Sant'Antonio","year":"2019","unstructured":"Sant\u2019Antonio E, Bonifacio M, Breccia M, Rumi E. A journey through infectious risk associated with ruxolitinib. Br J Haematol. 2019;187(3):286\u201395.","journal-title":"Br J Haematol"},{"issue":"4","key":"3421_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/s41375-020-01018-y","volume":"35","author":"AM Vannucchi","year":"2021","unstructured":"Vannucchi AM, Sordi B, Morettini A, Nozzoli C, Poggesi L, Pieralli F, Bartoloni A, Atanasio A, Miselli F, Paoli C, et al. Compassionate use of JAK1\/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. Leukemia. 2021;35(4):1121\u201333.","journal-title":"Leukemia"},{"issue":"7","key":"3421_CR18","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41375-020-0891-0","volume":"34","author":"F La Rosee","year":"2020","unstructured":"La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, Fellhauer M, Henkes M, Kumle B, Russo SG, et al. The Janus kinase 1\/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34(7):1805\u201315.","journal-title":"Leukemia"},{"key":"3421_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.","journal-title":"BMC Med"},{"key":"3421_CR20","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"6","key":"3421_CR21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, et al. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367\u201376.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3421_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","volume":"10","author":"EW Ely","year":"2022","unstructured":"Ely EW, Ramanan AV, Kartman CE, de Bono S, Liao R, Piruzeli MLB, Goldman JD, Saraiva JFK, Chakladar S, Marconi VC, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022;10(4):327\u201336.","journal-title":"Lancet Respir Med"},{"issue":"9","key":"3421_CR23","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1093\/cid\/cit530","volume":"57","author":"W Liu","year":"2013","unstructured":"Liu W, Lu QB, Cui N, Li H, Wang LY, Liu K, Yang ZD, Wang BJ, Wang HY, Zhang YY, et al. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in china who had severe fever with thrombocytopenia syndrome. Clin Infect Dis. 2013;57(9):1292\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"3421_CR24","doi-asserted-by":"publisher","first-page":"e0009103","DOI":"10.1371\/journal.pntd.0009103","volume":"15","author":"K Suemori","year":"2021","unstructured":"Suemori K, Saijo M, Yamanaka A, Himeji D, Kawamura M, Haku T, Hidaka M, Kamikokuryo C, Kakihana Y, Azuma T, et al. A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome. PLoS Negl Trop Dis. 2021;15(2):e0009103.","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"3421_CR25","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jiac.2017.11.004","volume":"24","author":"S Nakamura","year":"2018","unstructured":"Nakamura S, Azuma M, Maruhashi T, Sogabe K, Sumitani R, Uemura M, Iwasa M, Fujii S, Miki H, Kagawa K, et al. Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome. J Infect Chemother. 2018;24(5):389\u201392.","journal-title":"J Infect Chemother"},{"issue":"5","key":"3421_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/v13050785","volume":"13","author":"T Kawaguchi","year":"2021","unstructured":"Kawaguchi T, Umekita K, Yamanaka A, Hara S, Yamaguchi T, Inoue E, Okayama A. Corticosteroids may have negative effects on the management of patients with severe fever with thrombocytopenia syndrome: a case-control study. Viruses. 2021;13(5):785.","journal-title":"Viruses"},{"issue":"2","key":"3421_CR27","doi-asserted-by":"publisher","first-page":"e0009128","DOI":"10.1371\/journal.pntd.0009128","volume":"15","author":"SI Jung","year":"2021","unstructured":"Jung SI, Kim YE, Yun NR, Kim CM, Kim DM, Han MA, Kim UJ, Kim SE, Kim J, Ryu SY, et al. Effects of steroid therapy in patients with severe fever with Thrombocytopenia syndrome: a multicenter clinical cohort study. PLoS Negl Trop Dis. 2021;15(2):e0009128.","journal-title":"PLoS Negl Trop Dis"},{"key":"3421_CR28","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.ijid.2022.07.001","volume":"122","author":"L Xiong","year":"2022","unstructured":"Xiong L, Xu L, Lv X, Zheng X. Effects of corticosteroid treatment in patients with severe fever with thrombocytopenia syndrome: a single-center retrospective cohort study. Int J Infect Dis. 2022;122:1026\u201333.","journal-title":"Int J Infect Dis"},{"key":"3421_CR29","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ijid.2022.06.058","volume":"122","author":"JR Yoo","year":"2022","unstructured":"Yoo JR, Lee KH, Kim M, Oh HJ, Heo ST. Tocilizumab therapy for IL-6 increment in a patient with non-fatal severe fever with thrombocytopenia syndrome. Int J Infect Dis. 2022;122:656\u20138.","journal-title":"Int J Infect Dis"},{"issue":"12","key":"3421_CR30","doi-asserted-by":"publisher","first-page":"e12462","DOI":"10.1016\/j.heliyon.2022.e12462","volume":"8","author":"S Wen","year":"2022","unstructured":"Wen S, Xu N, Wang G. Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS). Heliyon. 2022;8(12):e12462.","journal-title":"Heliyon"},{"issue":"21","key":"3421_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/JVI.01159-19","volume":"93","author":"ML DeDiego","year":"2019","unstructured":"DeDiego ML, Martinez-Sobrido L, Topham DJ. Novel functions of IFI44L as a feedback regulator of host antiviral responses. J Virol. 2019;93(21):10\u2013128.","journal-title":"J Virol"},{"issue":"8","key":"3421_CR32","doi-asserted-by":"publisher","first-page":"e507","DOI":"10.1016\/S2589-7500(21)00102-3","volume":"3","author":"N Xu","year":"2021","unstructured":"Xu N, Hao F, Dong X, Yao Y, Guan Y, Yang L, Chen F, Zheng F, Li Q, Liu W, et al. A two-transcript biomarker of host classifier genes for discrimination of bacterial from viral infection in acute febrile illness: a multicentre discovery and validation study. Lancet Digit Health. 2021;3(8):e507\u201316.","journal-title":"Lancet Digit Health"},{"issue":"6","key":"3421_CR33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1182\/blood.2020006075","volume":"136","author":"LK Meyer","year":"2020","unstructured":"Meyer LK, Verbist KC, Albeituni S, Scull BP, Bassett RC, Stroh AN, Tillman H, Allen CE, Hermiston ML, Nichols KE. JAK\/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020;136(6):657\u201368.","journal-title":"Blood"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03421-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-024-03421-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-024-03421-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,19]],"date-time":"2024-05-19T20:05:57Z","timestamp":1716149157000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-024-03421-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3421"],"URL":"https:\/\/doi.org\/10.1186\/s12916-024-03421-z","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]},"assertion":[{"value":"27 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Qilu Hospital of Shandong University (KYLL-202206\u2013011-1). All patients signed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All of the authors agreed to submit and publish the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"204"}}